Singapore markets closed

Straits Times Index
3,426.47
-3.98(-0.12%)
Nikkei
37,667.41
-202.10(-0.53%)
Hang Seng
17,021.31
+16.34(+0.10%)
FTSE 100
8,285.71
+99.36(+1.21%)
Bitcoin USD
68,031.08
+915.96(+1.36%)
CMC Crypto 200
1,378.36
+47.75(+3.59%)

Viatris Inc. (VTRS)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

12.08

+0.32

(+2.72%)

At close: 04:00PM EDT

12.09

+0.01

(+0.08%)

After hours:

06:44PM EDT

Trade prices are not sourced from all markets

All

Zacks
3 Generic Drug Stocks to Watch Amid Improving Market Prospects
With the ease in inflationary pressure, the Zacks Medical - Generic Drugs industry is expected to benefit from declining costs. New product launches provide some respite to AMPH, RDY, and TEVA.
PR Newswire
Viatris Brings to Completion All Previously Announced Divestitures With the Closing of its Over-the-Counter Business Divestiture
Viatris Inc. (NASDAQ: VTRS), a global healthcare company, today announced that it has closed the divestiture of its Over-the-Counter (OTC) business to Cooper Consumer Health, a leading European over-the-counter drug manufacturer and distributor, bringing to substantial completion all previously announced divestitures.
PR Newswire
U.S. Department of Justice Informs Viatris That It No Longer Considers Mylan a Subject of Generic Drug Industry Antitrust Investigation
Viatris Inc. (NASDAQ: VTRS) today announced that the Antitrust Division of the U.S. Department of Justice ("DOJ") has advised that it no longer considers Mylan, and its former President, Rajiv Malik, a subject of its antitrust investigation in the generic drug industry. The Civil Division of the DOJ has also informed the Company that it does not expect to take any further actions in connection with a civil investigative demand related to the pricing and sales of generic drug products.